



IBD attacks from multiple angles. We should too.

Inflammatory bowel disease (IBD) is a complex and debilitating disease that significantly affects people's lives. The most common forms of IBD are Crohn's disease and ulcerative colitis. Both cause inflammation in the gastrointestinal tract, which can lead to fibrosis (an excessive buildup of scar tissue in the intestinal wall). There are many approved treatments for IBD. But unfortunately, they don't always work for everyone. Which is why we're conducting a program of clinical studies to see if an investigational medicine that targets not only inflammation, but also fibrosis, could improve the symptoms and quality of life of people living with IBD.

See reverse for more information.



Who can take part in our studies?

We're looking for people to join who:

- Are aged between 16 and 80*
- Are diagnosed with moderate to severely active Crohn's disease or ulcerative colitis
- Have tried at least one medicine for their condition that didn't work, stopped working, or caused unacceptable unwanted effects

*Eligibility for people aged 16 and 17 depends on local guidelines and regulations.

What will taking part involve?

If you join a clinical study in this program, you could take part for around 7 months to 1 year and 4 months. During this time, you'll be randomly assigned to receive either the investigational medicine or a placebo, both of which will be given as intravenous (IV) infusions, or IV infusions followed by subcutaneous (under the skin) injections approximately once a month. You'll have at least eight visits so that we can monitor your health.

What happens next?

If you would like to learn more, please contact the study team using the details below or scan the QR code for more information. Your decision to participate could have a positive personal impact and may help other people living with IBD in the future.

[study team contact details]

